New cancer drug combo enters first human safety tests

NCT ID NCT04491942

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

Summary

This is an early-stage safety study testing a new drug called BAY 1895344 when given with standard chemotherapy drugs (cisplatin with or without gemcitabine). The main goals are to find the safest dose and understand the side effects in people with advanced solid tumors that have spread, with a special focus on bladder cancer. The study will also look for early signs that the combination might help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032, United States
National Cancer Institute Developmental Therapeutics Clinic

Bethesda, Maryland, 20892, United States
National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
University Health Network-Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States
University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.